OpenAI and DeepMind take different paths in AI drug discovery

DeepMind's Isomorphic Labs has raised $2.1 billion and now targets first clinical trials in late 2026, building on protein structure prediction. OpenAI is betting on agents instead: GPT-Rosalind, Rosalind Workbench and the Orchestra module track drug programs, backed by its Orchestra Bio acquisition.

Digit

Open source

OpenAI and DeepMind take different paths in AI drug discovery

Isomorphic Labs raised $2.1 billion from Thrive Capital, GV, CapitalG, MGX and Temasek
Isomorphic's first clinical trials slipped from late 2025 to late 2026
OpenAI uses GPT-Rosalind, Rosalind Workbench and Orchestra agents to track programs
OpenAI partners include Novo Nordisk and Moderna; Isomorphic works with Eli Lilly and Novartis

#OpenAI#DeepMind#IsomorphicLabs

Meta, Google DeepMind, Isomorphic Labs invest $300M in Biohub for open biology AI datasets

AstraZeneca strikes $1.5b AI drug discovery deal with Insitro

Science

NASTIC tech tracks proteins in living neurons for neurodegenerative drug discovery

Science

OpenAI and DeepMind take different paths in AI drug discovery

Meta, Google DeepMind, Isomorphic Labs invest $300M in Biohub for open biology AI datasets

AstraZeneca strikes $1.5b AI drug discovery deal with Insitro

NASTIC tech tracks proteins in living neurons for neurodegenerative drug discovery

INmune Bio and Quantum Computing Inc. to Use Quantum Optimization for Alzheimer's Drug Discovery